cyproterone acetate / Generic mfg. - LARVOL DELTA

The Impact of Common Medications on Male Fertility: An Updated Systematic Review. (PubMed, Andrology) - "In this updated review, evidence-based recommendations for clinical management and for possible fertility preservation or contraception in men of reproductive age receiving common acute or chronic medical treatment are provided, with the goal of making these data more readily available to medical staff."

Journal • Review • Infertility

Divergent Effects of Estradiol Regimens on Protein S and Global Coagulation in Transgender Women. (PubMed, Thromb Haemost) - "The two GAHT protocols were associated with different laboratory hemostatic patterns, including a reduction in free Protein S antigen with sublingual estradiol. These findings warrant further evaluation in larger mechanistic studies."

Clinical • Journal • PROS1

Treatment patterns and survival outcomes in metastatic castration-resistant prostate cancer in the Brazilian population: LACOG 1818. (ASCO-GU 2025) - P | "LACOG 1818 study demonstrated significant disparities in treatment patterns and survival outcomes between public and private settings for Brazilian pts with mCRPC. Pts with private coverage had longer OS and CSS. These findings underscore the need for improved access to novel therapies and comprehensive cancer care in Brazil's public healthcare system to reduce survival disparities."

Clinical • Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Impact of gender-affirming hormone therapy on the endocrine axis and male germ cells. (PubMed, Reprod Fertil) - "To address the hypothesis that treatment effects are not homogeneous, we selected 24 persons from a cohort of 453 persons assigned male at birth, based on a similar dose of cyproterone acetate (Androcur, 10 or 12.5 mg/day)...Finally, Group 4 largely showed loss of germ cells and included the oldest people in the study. These results are relevant for counselling, as individuals need to be informed of the different effects that hormonal therapy can have with regard to sperm production and thereby fertility."

Journal • Endocrine Disorders

Treatment of Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy. (PubMed, Prostate) - "Hormonal agents such as cyproterone acetate and estrogen appear to be the most effective treatments, although they are associated with side effects. Non-pharmacological options like acupuncture and CBT may offer some benefit, while dietary supplements seem to be ineffective. Future studies are needed also to evaluate newer treatments, such as fezolinetant, in this patient population."

Journal • Review • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Exogenous Hormones and Their Clinical Implications for the Development and Growth of Meningioma Tumours. (PubMed, J Clin Med) - "Risk associated with synthetic progestin-containing compounds such as depot medroxyprogesterone and desogestrel contraceptives was higher and related to duration of use. Highly potent synthetic progestins including cyproterone acetate (CPA) carried the strongest risk profile and showed a strong association with multiple meningiomas and anterior/middle skull base location. In conclusion, there is strong evidence for a link between meningioma incidence and highly potent synthetic progestins such as CPA, but further evidence is needed regarding menopausal hormone therapy and broadly defined oral contraceptives, as well as the doses and durations that are associated with clinically relevant risk. There is a space for translational research in this area to better understand the molecular basis underlying the relationship between hormones and meningioma growth."

Journal • Review • Brain Cancer • CNS Tumor • Meningioma • Oncology • Solid Tumor

Anti-androgen therapy in polyendocrine metabolic ovary syndrome (PMOS, formerly PCOS): efficacy, safety, and phenotype-oriented clinical decision-making. (PubMed, J Ovarian Res) - "In this review, we provided a comprehensive molecular analysis of hyperandrogenism in PMOS/PCOS, systematically evaluated the efficacy of key anti-androgen agents, including combined oral contraceptives, spironolactone, cyproterone acetate, finasteride, and emerging therapies, and assessed their safety profiles concerning metabolic, reproductive, and general adverse effects. We further examine integrated management strategies combining pharmacotherapy, lifestyle modifications, insulin sensitizers such as metformin, and emerging integrative approaches...This review also addressed current controversies, including uncertainties regarding long-term cardiovascular safety, optimal treatment duration, and the lack of predictive biomarkers, outlining future research priorities. Finally, we proposed a practical phenotype-guided framework for the stratified clinical management of hyperandrogenic PMOS/PCOS."

Journal • Review • Acne Vulgaris • Alopecia • Cardiovascular • CNS Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Polyendocrine Metabolic Ovarian Syndrome

Prediction of meningioma shrinkage after cyproterone acetate cessation. (PubMed, Neurooncol Adv) - "Tumor burden and age at CPA exposure are major predictors of meningioma shrinkage after treatment discontinuation. Early volumetric changes provide additional prognostic value and significantly improve predictive accuracy."

Journal • Brain Cancer • Meningioma • Oncology • Solid Tumor

Distinct effects of feminizing and masculinizing gender-affirming hormone therapy on fibrinogen γ' (ISTH 2026) - "Feminizing GAHT comprised three treatment regimens (oral/transdermal estradiol and cyproterone acetate (CPA)), whereas masculinizing GAHT comprised seven treatment regimens (intramuscular/transdermal testosterone and progestin)...This work was supported by The University of Southern Denmark and the Region of Southern Denmark. DOI*10.1016/j.rpth.2026.104234"

Cardiovascular • Hematological Disorders • Thrombosis

Contraceptive Progestogens and Incident Meningioma. (PubMed, JAMA Netw Open) - "For combined oral contraceptives, the estimated odds ratios (ORs) for the association between use of progestogens and meningioma were 1.61 (95% CI, 1.00-2.59) with cyproterone, 1.66 (95% CI, 1.31-2.10) with desogestrel, 1.58 (95% CI, 1.05-2.37) with drospirenone, 1.44 (95% CI, 1.17-1.77) with gestodene, 1.40 (95% CI, 1.12-1.76) with levonorgestrel, 1.38 (95% CI, 0.77-2.47) with norethisterone, and 1.04 (95% CI, 0.70-1.54) with norgestimate. In this case-control study conducted using data from the entire Danish population, recent use of the contraceptive progestogens cyproterone, desogestrel, drospirenone, gestodene, levonorgestrel, injectable medroxyprogesterone, and high-dose IUD was associated with increased risk of meningioma. These findings are considered relevant information for the treated women and the prescribing physicians."

Journal • Brain Cancer • Long-acting Reversible Contraceptives • Meningioma • Oncology • Solid Tumor

Progestin therapy in premenopausal women with incidental meningioma-a narrative review and recommendations for women's health specialists. (PubMed, Gynecol Endocrinol) - "Consistent associations with increased meningioma risk were observed for high-dose or prolonged exposure to cyproterone acetate, chlormadinone acetate, nomegestrol acetate, and medroxyprogesterone acetate...Evidence for other progestins, including desogestrel, dienogest, levonorgestrel, and the levonorgestrel-releasing intrauterine system, remains limited and less conclusive...When hormonal treatment remains necessary, the lowest effective dose and regular neuro-oncologic monitoring are recommended. Increased awareness and individualized counseling are essential to optimize hormonal management in women at risk of meningioma."

Journal • Review • Brain Cancer • Endometriosis • Gynecology • Meningioma • Oncology • Solid Tumor • Women's Health

Impact of Gender-Affirming Hormone Therapy on Lipid Parameters in AMAB Transgender Patients: The Pivotal Role of Antiandrogen Treatment (ENDO 2026) - "Use of cyproterone acetate (CPA) in combination with estrogens was associated with reductions in total cholesterol (-53.3%, P < 0.001), LDL cholesterol (-20 mg/dL, P = 0.043), and triglycerides (-53.3%, P < 0.001) compared with spironolactone, and with reductions in total cholesterol (-41.4%, P = 0.007), triglycerides (-41.5%, P = 0.007), and HDL cholesterol (-7.65 mg/dL, P = 0.031) compared with estrogen monotherapy. While acknowledging the complex effects on lipid metabolism and the potential reduction in HDL cholesterol, CPA may be associated with an overall more favorable lipid profile. Further longitudinal studies will be required to confirm these findings and to assess their association with long-term vascular outcomes."

Clinical • Dyslipidemia • Metabolic Disorders

Feminizing and masculinizing gender-affirming hormone therapy affects fibrin clot characteristics in opposite directions. (PubMed, Res Pract Thromb Haemost) - "Clot formation (velocity [V max], maximum absorbance [MA], and overall hemostasis potential [OHP]), clot lysis, and structure (fiber density and diameter) were studied by turbidity at baseline and after 12 months of feminizing GAHT (3 groups of oral/transdermal estradiol and cyproterone acetate) or masculinizing GAHT (7 groups of intramuscular/transdermal testosterone)...The procoagulant effect was most evident with oral feminizing GAHT. This large cohort study provides important insights into the mechanisms linking GAHT to thrombotic risk."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

Use of Testosterone-Lowering Medication in Patients With Intellectual Disabilities and Problematic Sexual Behaviour: A Case Series. (PubMed, Case Rep Psychiatry) - "Monitoring and access varied regionally. TLM may be effective in selected patients with intellectual disability but requires careful monitoring and ethical oversight."

Journal • Cardiovascular • CNS Disorders • Depression • Developmental Disorders • Hypertension • Mental Retardation • Osteoporosis • Psychiatry • Rheumatology

Prognostic potential of PROSTest for predicting outcome in ADT-treated Black South African prostate cancer patients. (ASCO 2026) - "Goserelin acetate alone or in combination with cyproterone acetate was administered. The PROSTest activity score determined pre- or post-ADT (first cycle) identifies PCa patients at risk for poor treatment outcomes."

Biomarker • Clinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Comparison of two menopausal hormone therapy regimens in managing menopausal symptoms: a retrospective study. (PubMed, BMC Womens Health) - "Femoston and Climen provide comparable short-term menopausal symptom relief. The more favorable lipid profile with Femoston, particularly its HDL-C benefit, may inform individualized regimen selection, especially in women without indications for antiandrogenic therapy. Prospective studies with longer follow-up are warranted to evaluate hard cardiovascular endpoints."

Journal • Retrospective data • Cardiovascular • CNS Disorders • Insomnia • Sleep Disorder

Use of progestogens and risk of intracranial meningioma: new data and clinical challenges (PubMed, Med Sci (Paris)) - "Studies based on the French national health data system (SNDS) have shown a dose-response relationship between the use of seven progestogens (including cyproterone acetate, nomegestrol, and chlormadinone) and the occurrence of meningioma. They have also confirmed a reduction in the risk after discontinuation of the progestogens. In France, measures to restrict prescriptions, screening by magnetic resonance imaging, and the discontinuation of high-risk progestogens, in cases of meningioma, have led to a 90 % reduction in the number of meningioma surgeries performed on women taking these high-risk progestogens."

Journal • Review • Brain Cancer • Gynecology • Meningioma • Oncology • Solid Tumor

Epidemiological and clinical data link depot medroxyprogesterone acetate to meningioma. (PubMed, Neuro Oncol) - "Previous epidemiological and clinical data have demonstrated that multiple progestins, such as cyproterone acetate (CPA), are linked to meningioma. More recently, international epidemiological studies have found a significantly increased risk of meningioma with depot medroxyprogesterone acetate (DMPA), a widely used injectable contraceptive sold under the trade name Depo-Provera...The risk of meningioma should be discussed with patients during DMPA counseling, and the utility of screening patients with prolonged DMPA exposure for meningiomas should be investigated. Further work is needed to elucidate the mechanisms of PR signaling in meningioma and to understand the complex interplay of tumor genomics, hormone exposure and signaling, and social and structural drivers of health that may contribute to disparities in meningioma."

Clinical data • Journal • Brain Cancer • Long-acting Reversible Contraceptives • Meningioma • Oncology • Solid Tumor

Exceptional Response to Short-course 177Lu-PSMA Radioligand Therapy in a Patient With Metastatic Hormone-sensitive Prostate Cancer. (PubMed, Clin Nucl Med) - "Androgen-deprivation therapy with goserelin, abiraterone, and cyproterone acetate reduced PSA to 44.29 ng/mL. Nine-month follow-up 99mTc-PSMA demonstrated complete regression of metastatic lesions. This case highlights the potential efficacy and safety of early 177Lu-PSMA therapy in high-volume mHSPC, suggesting a role for optimizing hormonal therapy outcomes."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Musculoskeletal Pain • Oncology • Pain • Prostate Cancer • Solid Tumor

Galactorrhea and Pituitary Microadenoma in an 18-Year-Old Transfeminine Youth: A Case Report. (PubMed, AACE Endocrinol Diabetes) - "Contributing factors included high-dose estradiol, cyproterone acetate, concomitant antiretroviral and antidepressant therapy, and frequent breast massage...Unsupervised GAHT in adolescents can lead to significant endocrine complications through multifactorial mechanisms. Early recognition, structured monitoring, and coordinated multidisciplinary care are crucial to balance gender-affirming goals with patient safety."

Journal • Endocrine Cancer • Oncology • Pediatrics • Pituitary Gland Carcinoma

Prescription of drugs: The Physician's duty to inform and medical liability, a complex and essential medico-legal obligation (PubMed, Gynecol Obstet Fertil Senol) - No abstract available

Journal

Association of hormone therapy with spheno-orbital meningiomas: bridging evidence and unknowns. (PubMed, Front Oncol) - "Hybrid strategies that combine hormone therapy cessation with surgery may be beneficial in selected cases, although prospective data are lacking. Standardized clinical guidelines and further studies are needed to clarify the role of hormone therapy in the management of SOM."

Journal • Review • Brain Cancer • Meningioma • Oncology • Solid Tumor

One-year changes in body composition and phase angle during feminizing gender-affirming hormone therapy: a longitudinal and comparative study. (PubMed, Front Endocrinol (Lausanne)) - "GAHT included estradiol with cyproterone acetate or spironolactone. These findings underscore the importance of comprehensive body composition assessments in AMAB individuals receiving feminizing GAHT. Further studies with longer follow-up periods and larger cohorts are needed to elucidate the long-term clinical significance of these changes."

Clinical • Journal • CNS Disorders

Hidradenitis Suppurativa and Hormonal Therapies in Transgender Individuals (AAD 2026) - "Limited evidence links testosterone-based masculinizing therapy to HS onset or worsening, while feminizing therapy effects varied by agent. The dermatologic response appears formulation-specific, with estrogen products improving HS, while cyproterone acetate and progesterone-based therapies exacerbate disease. These findings highlight the need for targeted research to better understand how gender-affirming therapies impact HS in order to inform management."

Clinical • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation

Bone Mineral Density in Transgender Women during the First Year of Gender – Affirming Hormone Therapy (ISGE 2026) - "Interventions: All patients received oral estradiol hemihydrate (6 mg/day), cyproterone acetate (50 mg/day), and micronized progesterone (200 mg/day for 10 days monthly, starting from the sixth month of therapy). Our results demonstrate that GAHT in transfemales may positively affect bone mineral density within the first year of treatment. Bone health monitoring and individualized risk assessment is important in clinical practice, especially in those with low bone mass. Long-term studies are need to evaluate the long-term effect of GAHT on bone health."

Clinical • Endocrine Disorders • Infertility • Sexual Disorders